The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of ...
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results